XDx and LabCorp enter non-hospital provider agreement for AlloMap molecular expression tests

XDx, Inc., a molecular diagnostics company focused on noninvasive gene expression tests to monitor immune-mediated conditions, today announced that it has entered into a multi-year agreement with Laboratory Corporation of America Holdings (LabCorp; NYSE:LH) to provide heart transplant patients eligible for XDx's AlloMap® test with the convenience of having their blood drawn at participating LabCorp sites across the United States. Under the terms of the agreement, LabCorp will be XDx's preferred third-party non-hospital provider for phlebotomy and specimen processing for all XDx AlloMap molecular expression tests conducted in North America. This expanded agreement follows a successful one-year pilot between the companies at select LabCorp blood draw sites. The XDx reference lab will also continue to perform the proprietary AlloMap test.

"We are delighted to expand our business relationship with LabCorp and pleased that this expansion will have a direct impact on patients. Those heart transplant recipients eligible for our AlloMap test will enjoy access to and the greater convenience of more than 1,700 patient service centers," said Pierre Cassigneul, president and CEO of XDx.